Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-396 in crizotinib-resistant ALK-positive NSCLC
CTR20170762Phase 2Active
- Sponsor
- Beta Pharma
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Beta Pharma. Started Aug 2017; status: active.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170762.